Novo Nordisk's New Obesity Drug: Game Changer? #shorts

Big news from Novo Nordisk! 🚀 Shares soared 10% after early trials of their groundbreaking weekly obesity drug, Amycretin, revealed an astounding average weight loss of 22% in just 36 weeks! This innovative treatment targets hunger hormones like GLP-1 and amylin, similar to their blockbuster drugs Wegovy and Ozempic. Conducted on 125 patients, the trial showed mostly mild side effects. Plus, an oral version of Amycretin is being tested with promising results! Is this the future of weight-loss treatments? We want to hear your thoughts in the comments below!

Like and share this video to spread the news!

#NovoNordisk #Amycretin #ObesityTreatment #WeightLoss #PharmaNews #Health #Innovation #MedicalBreakthrough #GLP1 #Wegovy #Ozempic #ObesityDrug #Science #Healthcare #Biotech #ClinicalTrials #Pharmaceuticals #HealthTech #WeightManagement #NewsUpdate